Cumberland Pharmaceuticals Inc. (CPIX)

Over the past six months, CPIX's stock price has been impacted by several events. These include the Q2 and Q3 2025 earnings reports, a strategic partnership with RedHill Biopharma to jointly commercialize Talicia, and the addition of an established FDA-approved product to its commercial portfolio. The stock also hit a 52-week low, saw news regarding a permanent CMS J-code for Caldolor injection, and experienced insider trading activity. The stock price moved over +5.20% to $3.95 and Cumberland Pharmaceuticals received FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy program, which caused the stock to rise by 15.04% to $4.36. The stock price fell below its 200-day and 50-day moving averages.

Information regarding the specific demand seasonality for Cumberland Pharmaceuticals, Inc.'s products and services is not readily available in the provided search results. Factors such as macroeconomic conditions, competition, and manufacturing capabilities are noted as influences on the company's operations, but not in the context of seasonal demand for its products.

Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products for niche hospital and specialty markets, including acute care, gastroenterology, and oncology support. The company markets established, high-margin therapies and invests in a late-stage clinical pipeline for rare diseases. Its major products include Acetadote injection for acetaminophen poisoning, Caldolor injection for pain and fever management, Kristalose oral solution for chronic constipation, Sancuso transdermal patch for nausea and vomiting in oncology patients, Vaprisol injection for hyponatremia, Vibativ injection for serious bacterial infections, and Talicia oral capsule for H. pylori infection. The company also has a pipeline product, ifetroban, which has completed Phase II clinical trials for conditions such as cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease, and is in Phase II clinical trials for systemic sclerosis and idiopathic pulmonary fibrosis.

Cumberland Pharmaceuticals is headquartered in Nashville, Tennessee. The company has been actively expanding its international market presence through partnerships and regulatory approvals, including the launch of Vibativ in Saudi Arabia and regulatory approval for its ibuprofen injection product in Mexico in 2025.

Cumberland Pharmaceuticals maintains a brand reputation centered on its mission to provide unique, high-quality prescription medicines to improve patient care, particularly in acute care, gastroenterology, and oncology. Positive Phase 2 data for ifetroban in Duchenne muscular dystrophy, regulatory approval of its ibuprofen injection in Mexico and the launch of Vibativ in Saudi Arabia, and receiving FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy program have likely reinforced its reputation. The company's consistent news flow highlights product milestones, commercialization agreements, and clinical study results, all of which generally contribute to a positive perception within its specialized markets.

Cumberland Pharmaceuticals Inc. has a mixed ownership structure. Insiders hold the largest block of shares, approximately 41.62% to 41.63%, with founder and CEO A.J. Kazimi individually holding 38.11%. Institutional investors own about 11.71% to 15.51% of the company's stock. Public companies and individual investors (retail investors) hold approximately 3.13% to 43.54% of the shares. Major institutional investors include Millennium Management LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, The Vanguard Group, Inc., Berkshire Asset Management LLC PA, Adage Capital Partners GP L.L.C., Bridgeway Capital Management LLC, and Boothbay Fund Management LLC.